Clean Yield Group Lowers Stock Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Clean Yield Group trimmed its holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 20.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 286,556 shares of the company's stock after selling 73,535 shares during the quarter. Takeda Pharmaceutical makes up about 1.4% of Clean Yield Group's holdings, making the stock its 23rd biggest position. Clean Yield Group's holdings in Takeda Pharmaceutical were worth $4,261,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. Farther Finance Advisors LLC raised its holdings in shares of Takeda Pharmaceutical by 123.6% in the 4th quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company's stock worth $47,000 after purchasing an additional 1,976 shares during the period. Crowley Wealth Management Inc. bought a new stake in Takeda Pharmaceutical during the fourth quarter worth approximately $52,000. Cromwell Holdings LLC purchased a new position in shares of Takeda Pharmaceutical during the fourth quarter valued at $61,000. Venturi Wealth Management LLC raised its position in Takeda Pharmaceutical by 554.7% during the fourth quarter. Venturi Wealth Management LLC now owns 5,028 shares of the company's stock valued at $67,000 after acquiring an additional 4,260 shares in the last quarter. Finally, Lindbrook Capital LLC boosted its holdings in Takeda Pharmaceutical by 65.0% during the fourth quarter. Lindbrook Capital LLC now owns 5,151 shares of the company's stock valued at $68,000 after acquiring an additional 2,029 shares during the period. 9.17% of the stock is currently owned by institutional investors and hedge funds.

Takeda Pharmaceutical Stock Performance

Shares of TAK stock traded down $0.06 on Wednesday, reaching $15.19. The stock had a trading volume of 1,675,283 shares, compared to its average volume of 1,942,570. The firm's 50-day moving average is $14.66 and its two-hundred day moving average is $14.13. The company has a quick ratio of 0.72, a current ratio of 1.31 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $48.32 billion, a price-to-earnings ratio of 37.96, a P/E/G ratio of 0.24 and a beta of 0.23. Takeda Pharmaceutical Company Limited has a 12 month low of $12.58 and a 12 month high of $15.43.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported $0.16 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.24 by ($0.08). Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. The business had revenue of $7.34 billion during the quarter, compared to the consensus estimate of $8.02 billion. On average, research analysts expect that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Morgan Stanley upgraded Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research report on Wednesday, April 2nd.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.